UBS Global Biopharma Conference 2026
Logotype for Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Axsome Therapeutics Inc

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Q3 performance and commercial trends

  • Q3 total net sales were $260 million, establishing a run rate above $1 billion for the first time.

  • AUVELITY sales were $208 million, up 53% YoY; underlying MDD growth accelerated YoY in Q3 versus Q2.

  • SUNOSI revenue was $48 million, including an $8.5 million milestone; SYMBRAVO generated about $4 million and continued to grow in scripts.

  • AUVELITY scripts for patients over 65 were 13.5% of Q3 total; using age as an ADA proxy implies roughly $30 million, though the age group also includes MDD patients.

  • Under-65 AUVELITY revenue grew 33% YoY in Q3 versus 31% in Q2, and rose slightly above 10% sequentially.

AUVELITY growth drivers and outlook

  • AUVELITY NBRxs grew more than 200% YoY, from 2,400 per week in Q1 to 3,800 in October; management expects NBRx growth to feed future TRx growth.

  • ADA-proxy NBRxs rose 260%, from about 1,000 per month before the April 2026 approval to 3,600 per month; ADA scripts doubled QoQ.

  • Sales force expanded from about 270 reps at the start of 2026 to more than 650 including long-term care; the community team entered the field in June, with impact expected within one to two quarters.

  • Prescriber feedback on AD agitation tolerability and efficacy has aligned with the label; sampling is beginning to convert to scripts, while primary-care adoption may take longer than specialist conversion.

  • Peak sales opportunity remains $8 billion, roughly split 50/50 between ADA and MDD; Q4 gross-to-net could tick up depending on mix, and management expects NBRx growth to support 2027 and beyond.

Pipeline and development plans

  • SUNOSI’s ENGAGE binge-eating study is expected to report top-line results in 2027; it is one of two studies needed for a label addition, and a positive result would lead to a prompt second study.

  • Management cited potential markets of $500 million-$1 billion for binge-eating disorder and $1 billion-$3 billion for ADHD; solriamfetol also has ongoing MDD with excessive daytime sleepiness and shift-work disorder studies.

  • Solriamfetol’s Schedule IV status and distinct tolerability and adverse-reaction profile may differentiate it from stimulant-treated indications, depending on trial results.

  • AXS-20 is undergoing tech transfer, with a Phase III schizophrenia trial planned for 2027; prior Phase II data were described as compelling, with potential differentiation in efficacy and tolerability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Axsome Therapeutics